Dr. DiSilvestro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Dudley St
Providence, RI 02905Phone+1 401-453-7520
Education & Training
- University of Oklahoma Health Sciences CenterFellowship, Gynecologic Oncology, 1996 - 1999
- Women and Infants Hospital of Rhode Island/Brown UniversityResidency, Obstetrics and Gynecology, 1990 - 1994
- University of Vermont College of MedicineClass of 1990
Certifications & Licensure
- RI State Medical License 1991 - 2026
- CT State Medical License 2003 - 2024
- MA State Medical License 1996 - 2024
- NY State Medical License 1999 - 2004
- OK State Medical License 1996 - 1999
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Start of enrollment: 2006 Feb 01
- Doxil and Gemcitabine in Recurrent Ovarian Cancer Start of enrollment: 2006 Apr 01
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsPopulation-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both ...Ignace Vergote, Isabelle Ray-Coquard, Daniel M. Anderson, Guilherme Cantuaria, Nicoletta Colombo
European Journal of Cancer. 2021-09-27 - 165 citationsOverall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim
Journal of Clinical Oncology. 2023-01-20 - 1656 citationsMaintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung Gie Kim, Ana Oaknin
The New England Journal of Medicine. 2018-10-21
Journal Articles
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Paul DiSilvestro, Carol Aghajanian, The New England Journal of Medicine
Other
- Adjuvant treatment of high-risk endometrial cancersDiSilvestro PA, Fleming G
http://www.uptodate.com/contents/adjuvant-treatment-of-high-risk-endometrial-cancers
UpToDate, Wolters Kluwer Health - 2012-11-13
Press Mentions
- The Challenges with Using Targeted Therapies in Ovarian Cancer SpaceMarch 25th, 2023
- SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 25th, 2023
- Key Advances and Advocacy Are Themes at SGO Annual MeetingMarch 21st, 2023
- Join now to see all
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: